FG-3180

N/A

Report date: 2025/09/24 14:01:37

Base Information

Drug NameFG-3180

Drug Alias Name89Zr-DFO-YS-589Zr-DFO-YS5

ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4]

Mechanisms of ActionPositron-emission tomography enhancersMembrane cofactor protein modulators

TargetsMembrane cofactor protein

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesFortis Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute Fortis Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A